SecBot SecBot
6-K ·Filed Aug 3, 2026

CGEN

COMPUGEN LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001178913-26-003756
Notable filing: 6-K
Actionable Insight • Neutral

This filing is a routine proxy statement with no new operational or financial disclosures. Monitor the upcoming annual meeting for any unexpected developments, but no immediate trading action is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.38
T+0 close · Aug 3, 2026 · via day close
Latest settled
−18.70%
T+60 · $1.94
Vs SPY
−20.48%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $2.38entry
  2. T+1 · 4mo ago 0.00%α −1.80% · $2.38
  3. T+5 · 3mo ago −1.68%α −3.71% · $2.34
  4. T+20 · 3mo ago +7.56%α +6.33% · $2.56
  5. T+60 · 21d ago −18.70%α −20.48% · $1.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Compugen Ltd. filed its proxy statement for the 2026 Annual General Meeting via Form 6-K. The meeting will cover the election of eight directors, approval of an amended compensation policy, and re-appointment of the auditor. This is a routine governance filing with no material financial data or operational updates, and the stock impact is expected to be neutral.

Key Facts

  • The 2026 Annual General Meeting is scheduled for September 10, 2026.
  • Shareholders will vote on the election of eight directors, including one new nominee (Dr. Michele Holcomb).
  • Shareholders will vote on an amended compensation policy, which formalizes a minimum one-year cliff vesting for equity awards.
  • Kost Forer Gabbay & Kasierer (EY Global) is proposed for re-appointment as independent auditor for FY2026.
  • The record date for voting is July 27, 2026.
  • As of July 30, 2026, the company had 94,727,926 ordinary shares outstanding.
  • All office holders as a group beneficially own 3.30% of outstanding shares.
  • Audit fees for FY2025 were $217,000, down from $222,000 in FY2024.

Financial Impact

No material financial impact. Routine governance and compensation policy updates.

Risk Factors

  • No material risks identified from this routine governance filing.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-003756
Document: zk2635809.htm0001178913-26-003756
Document: 0001178913-26-003756-index-headers.html0001178913-26-003756
Document: 0001178913-26-003756-index.html0001178913-26-003756
Document: 0001178913-26-003756.txt0001178913-26-003756

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 3, 2026